中国临床药理学杂志2024，Vol.40Issue(15)：2265-2268,4.DOI:10.13699/j.cnki.1001-6821.2024.15.024
去甲氧柔红霉素或柔红霉素联合阿糖胞苷治疗急性髓系白血病患者的安全性分析
Safety analysis of idarubicin or daunorubicin combined with cytarabine in the treatment of patients with acute myeloid leukemia
摘要
Abstract
Objective To analyze the safety of idarubicin or daunorubicin combined with cytarabine in the treatment of patients with acute myeloid leukemia.Methods The Chinese Biomedical Database,Chinese Journal Full-text Database,Chinese Science and Technology Journal Full-text Database,Wanfang Database,Embase,PubMed,Cochrane Library were searched.The randomized controlled trials(RCTs)of idarubicin combined with cytarabine(treatment group)and daunorubicin combined with cytarabine(control group)were collected.The search time was from 2014-01-01 to 2024-02-23.RevMan 5.4 software was used to perform meta-analysis,sensitivity analysis and publication bias analysis on adverse drug reactions of the included studies.Results A total of 11 RCTs involving 1 818 patients were included in the Meta-analysis.The treatment and control groups were enrolled 912 and 906 cases,respectively.The results of meta-analysis showed that the total incidence of adverse drug reactions in the treatment group and the control group was 22.9％(56 cases/245 cases)and 42.9％(105 cases/245 cases),respectively,and the difference was statistically significant[relative risk(RR)=0.53,95％confidence interval(CI)=0.41-0.69,P＜0.001)].In the specific adverse drug reactions,there were no statistically significant differences in the incidence of hematological toxicity,digestive system toxicity,cardiac toxicity,liver and kidney toxicity,infection,bleeding between the two groups(all P＞0.05).Sensitivity analysis showed that the results were stable and reliable.The results of publication bias analysis showed that this study was less likely to have publication bias.Conclusion The incidence of adverse drug reactions of idarubicin combined with cytarabine in the treatment of patients with acute myeloid leukemia is significantly lower than that of daunorubicin combined with cytarabine,so the former has better safety.关键词
去甲氧柔红霉素/柔红霉素/阿糖胞苷/急性髓系白血病/安全性Key words
idarubicin/daunorubicin/cytarabine/acute myelogenous leukemia/safety分类
医药卫生引用本文复制引用
陈春红,徐鲁杰,刘璐,任美娟,张潇丹,闫美兴..去甲氧柔红霉素或柔红霉素联合阿糖胞苷治疗急性髓系白血病患者的安全性分析[J].中国临床药理学杂志,2024,40(15):2265-2268,4.基金项目
山东省第二批药品临床综合评价基金资助项目(2022YZ021) （2022YZ021）
